Who
Michael W. Rogers
Director
Company insider
Files Form 4 as: Director, Akebia Therapeutics; Director, Aravive; Director, EyePoint; Chief Financial Officer, Whitehawk Therapeutics; Director, Keryx Biopharmaceuticals; Chief Financial Officer, Acorda Therapeutics; Director, Fortress Biotech; EVP, CFO and Treasurer, BG Medicine.
In numbers
- Trades disclosed
- 108
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $406K
- Companies
- 9
- Companies where not an officer
- 5
- First trade
- 17 Feb 2006
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —35,700 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —53,600 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —53,600 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —35,700 at $0.00 | filing |
| 10 Jun 2025filed 11 Jun 2025 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —53,600 at $0.00 | filing |
| 10 Jun 2025filed 11 Jun 2025 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —35,700 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 23 Sep 2022filed 26 Sep 2022 | Araviveoption or derivative | SEC FORM 4 Code A | —97,063 at $0.00 | filing |
| 8 Jun 2022filed 9 Jun 2022 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,100 at $0.00 | filing |
| 8 Jun 2022filed 9 Jun 2022 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —13,700 at $0.00 | filing |
| 10 Sep 2021filed 13 Sep 2021 | Araviveoption or derivative | SEC FORM 4 Code A | —22,812 at $0.00 | filing |
| 2 Jun 2021filed 3 Jun 2021 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,100 at $0.00 | filing |
| 2 Jun 2021filed 3 Jun 2021 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —13,700 at $0.00 | filing |
| 15 Sep 2020filed 17 Sep 2020 | Araviveoption or derivative | SEC FORM 4 Code A | —15,024 at $0.00 | filing |
| 15 Sep 2020filed 17 Sep 2020 | Araviveoption or derivative | SEC FORM 4 Code A | —14,987 at $0.00 | filing |
| 5 Jun 2020filed 9 Jun 2020 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,100 at $0.00 | filing |
| 5 Jun 2020filed 9 Jun 2020 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —13,700 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.